Concepts (77)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rifampin | 2 | 2021 | 197 | 0.330 |
Why?
|
| Anti-HIV Agents | 3 | 2021 | 1324 | 0.290 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 3 | 2021 | 85 | 0.250 |
Why?
|
| Immunogenicity, Vaccine | 2 | 2021 | 103 | 0.220 |
Why?
|
| HIV-1 | 3 | 2020 | 1260 | 0.210 |
Why?
|
| HIV Infections | 5 | 2021 | 5097 | 0.210 |
Why?
|
| Adenine | 2 | 2020 | 91 | 0.200 |
Why?
|
| Antibodies, Neutralizing | 2 | 2021 | 303 | 0.190 |
Why?
|
| Pregnancy Outcome | 1 | 2021 | 117 | 0.180 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 1 | 2020 | 14 | 0.180 |
Why?
|
| Raltegravir Potassium | 1 | 2019 | 14 | 0.170 |
Why?
|
| Phosphorous Acids | 1 | 2019 | 14 | 0.160 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2019 | 47 | 0.160 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2020 | 155 | 0.150 |
Why?
|
| Obesity | 1 | 2021 | 367 | 0.150 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2020 | 472 | 0.150 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2020 | 200 | 0.140 |
Why?
|
| Respiratory Tract Infections | 1 | 2020 | 266 | 0.140 |
Why?
|
| Piperazines | 3 | 2021 | 82 | 0.130 |
Why?
|
| Oxazines | 3 | 2021 | 81 | 0.130 |
Why?
|
| Pyridones | 3 | 2021 | 100 | 0.130 |
Why?
|
| Anti-Retroviral Agents | 1 | 2019 | 551 | 0.120 |
Why?
|
| Tuberculosis | 1 | 2019 | 543 | 0.110 |
Why?
|
| Humans | 8 | 2021 | 14537 | 0.110 |
Why?
|
| Young Adult | 4 | 2021 | 2498 | 0.110 |
Why?
|
| Adolescent | 4 | 2021 | 2985 | 0.100 |
Why?
|
| Female | 6 | 2021 | 9103 | 0.100 |
Why?
|
| Adult | 5 | 2021 | 5913 | 0.100 |
Why?
|
| Viral Load | 3 | 2020 | 819 | 0.100 |
Why?
|
| Alanine | 2 | 2021 | 31 | 0.090 |
Why?
|
| Emtricitabine | 2 | 2021 | 78 | 0.090 |
Why?
|
| Alkynes | 2 | 2021 | 117 | 0.090 |
Why?
|
| Cyclopropanes | 2 | 2021 | 123 | 0.090 |
Why?
|
| Benzoxazines | 2 | 2021 | 123 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2021 | 272 | 0.090 |
Why?
|
| Pregnancy | 3 | 2021 | 1862 | 0.090 |
Why?
|
| Tenofovir | 2 | 2021 | 171 | 0.090 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 279 | 0.080 |
Why?
|
| Vaccination | 2 | 2021 | 365 | 0.080 |
Why?
|
| Male | 4 | 2021 | 6754 | 0.080 |
Why?
|
| Middle Aged | 3 | 2021 | 3601 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2019 | 656 | 0.070 |
Why?
|
| Child, Preschool | 2 | 2021 | 1748 | 0.060 |
Why?
|
| Infant | 2 | 2021 | 2244 | 0.060 |
Why?
|
| Child | 2 | 2021 | 2242 | 0.060 |
Why?
|
| Cross Reactions | 1 | 2021 | 44 | 0.050 |
Why?
|
| Safety | 1 | 2021 | 34 | 0.050 |
Why?
|
| Vaccine Potency | 1 | 2021 | 16 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2021 | 39 | 0.050 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 65 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2021 | 175 | 0.040 |
Why?
|
| Hypoxia | 1 | 2020 | 12 | 0.040 |
Why?
|
| Poisson Distribution | 1 | 2020 | 18 | 0.040 |
Why?
|
| Viral Fusion Proteins | 1 | 2020 | 13 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2020 | 31 | 0.040 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2020 | 30 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 150 | 0.040 |
Why?
|
| Body Weight | 1 | 2020 | 111 | 0.040 |
Why?
|
| Mutation | 1 | 2021 | 306 | 0.040 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2020 | 73 | 0.040 |
Why?
|
| Uracil | 1 | 2019 | 7 | 0.040 |
Why?
|
| Prodrugs | 1 | 2019 | 10 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 21 | 0.040 |
Why?
|
| Nanoparticles | 1 | 2020 | 104 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 156 | 0.040 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2019 | 33 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 284 | 0.040 |
Why?
|
| Body Composition | 1 | 2020 | 153 | 0.040 |
Why?
|
| Bone Density | 1 | 2019 | 107 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 231 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2019 | 303 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2020 | 889 | 0.040 |
Why?
|
| Hospitalization | 1 | 2020 | 418 | 0.040 |
Why?
|
| South Africa | 2 | 2021 | 7596 | 0.040 |
Why?
|
| Coinfection | 1 | 2019 | 276 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2020 | 1479 | 0.030 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2019 | 529 | 0.030 |
Why?
|